Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction

New data indicates that Eli Lilly's investigational oral medication, orforglipron, produced considerable weight loss in clinical studies. This offers a potential new treatment avenue for individuals grappling with obesity and associated health issues. The medication is anticipated to be available next year.

New data reveals that orforglipron, Eli Lilly's oral weight-loss drug candidate, exhibited significant weight reduction in clinical studies, presenting a possible new avenue for those struggling with obesity and associated conditions. The drug is anticipated to be available in 2024.

On Thursday, December 7, 2023, Eli Lilly revealed that its experimental oral drug, orforglipron, resulted in weight loss of up to 29% during clinical trials. The clinical trials included participants who were obese or overweight and had at least one weight-related health condition. The most substantial weight reduction was observed in patients receiving the highest dose of orforglipron.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

The drug functions by activating the GLP-1 receptor, akin to widely used injectable weight-loss drugs like Wegovy and Mounjaro, both also manufactured by Eli Lilly. Health tracking apps like Shotlee can help monitor progress with such medications. However, orforglipron is administered orally, potentially providing a more convenient option for patients.

Source Information

Originally published by News Directory 3.Read the original article →

Keep exploring

More on orforglipron

Articles covering orforglipron dosing, side effects, and clinical updates.

Health & Wellness

Oral GLP-1 Drugs May Quiet the Brain's Food Craving Circuit

New research suggests that oral GLP-1 medications, including those used for weight loss and diabetes, might work by influencing the brain's reward pathways, potentially reducing cravings for enjoyable foods and offering insights into treating substance use disorders.

8 min read

Medication News

New Weight Loss Pill Beats Oral Ozempic in Major Clinical Trial

A recent Phase 3 clinical trial indicates that orforglipron offers superior blood sugar control and weight loss compared to oral semaglutide, though side effects remain a consideration.

9 min read

Health & Wellness

Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide

A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.

6 min read

Same topic: weight loss

All weight loss articles →

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

More in Health

Health

Another Round of Weight-Loss Medications is on the Horizon

The demand for weight-loss drugs is surging. New medications promise increased effectiveness and easier administration, including oral options. Several pharmaceutical companies are developing improved injectable drugs.

4 min read

Health

GLP-1s: Understanding the Evolution of Weight-Loss Medications

Weight-loss drugs, particularly those mimicking GLP-1, have gained significant traction. This article delves into their functionality, efficacy, side effects, accessibility challenges, and the emergence of more accessible pill versions.

6 min read

Health

New Research Shows Hidden Caveats of Substantial Weight Loss from GLP-1 Medications Like Ozempic

Analyses of GLP-1 receptor agonists for weight management show clinically significant weight loss compared to placebo. However, long-term safety and potential side effects remain uncertain. Financial ties influencing study results are also a concern.

3 min read